




**Biopharma
Sustainability
Roundtable**

Biopharma Sustainability Roundtable Overview 2023


Produced by

The Biopharma Sustainability Roundtable Team



The Biopharma Sustainability Roundtable

BSRT for short



Who we are

The Biopharma Sustainability Roundtable (BSRT) is an independent sector-specific network that connects and supports senior biotech and pharma leaders who are driving the biopharma sustainability agenda forward. Our participants are pharma and biotech companies globally.

What we do

- The BSRT organizes, facilitates, and delivers an annual program of online topical forums, peer-to-peer networks, group initiatives, in-person meetings, and bespoke advisory services.
- Our annual program addresses a wide range of global environmental, social, and governance (ESG) topics, from strategy through governance, targets and performance, to operations, and reporting. Themes and content are driven by the sector's current and emerging priorities and are developed in consultation with participating companies.
- The BSRT has become recognized as the leading biopharma sustainability network, and the only one with a dual focus on the sector and its sustainability topics.

What makes the BSRT different

- **Industry specific** – We deal exclusively with biopharma to facilitate deeper and more relevant discussions
- **Sustainability focus** – We address a comprehensive range of environmental, social and governance topics on the industry's agenda
- **Great conversations** – We facilitate peer-to-peer interactions that help drive sustainability performance
- **Engagement is expected** – Participant-driven agendas, time for networking, and limited meeting size
- **No hidden agendas** – We carefully manage consultant and other third-party participation
- **Frank and open discussion** – All events held under the Chatham House Rule for professional confidentiality

Our Activities

What we offer BSRT participants

Topical Forums

- Expert online discussions on topics of current interest to the BSRT community, with invited thought leaders and/or company case studies
- Open to all designated colleagues of BSRT subscriber companies, taking place year-round

Biopharma Sustainability Roundtable Conference

- Our annual flagship face-to-face meeting, bringing together BSRT company participants for networking and personal connections
- Focus on Biopharma sector and Sustainability topics of highest priority to member companies
- World-class speakers, leading-edge case studies, and expert panel discussions
- Two-days, open to all BSRT companies

Biopharma Sustainability Investor Day

- The annual one-day face-to-face meeting between BSRT company participants and the BSRT capital markets network
- Direct dialog about the biopharma sector Sustainability and ESG agenda

Peer-to-Peer Networks

- **BSRT Leaders Check-in:** A monthly opportunity for brief, timely, and confidential on-line discussions about emerging Sustainability concerns, questions, and challenges that companies are facing. Brings together the one or two primary contacts at each BSRT participant company.
- **Chief Sustainability Officers Council:** A platform for CSO-level spontaneous and informal on-line discussions about top-of-mind issues and sector challenges, meeting tri-annually. Exclusive to CSOs or equivalent, i.e., the most senior sustainability executive in each BSRT participant company.
- **Non-Executive Directors Network:** A platform for NEDs at BSRT participant companies to discuss sector-specific challenges and insights with peers.

Member-driven Initiatives

- Biopharma Investor ESG Communications Initiative, since 2018
- Biopharma Human Rights Focus Group, since 2022
- Current and future Initiatives are facilitated for sub-groups of interested companies

Bespoke Advisory Services

- For BSRT participating companies: Sustainability leadership onboarding, Coaching, Sparring partner, Reviewer, Strategy advisor
- For third parties with a nexus to biopharma: Strategic ESG advisor, Co-organizer of Sector ESG Forums or Workshops, Trends and outlooks advisor

Our Participants

Global pharma and biotech companies

Participation includes leading global pharma and biotech companies, represented by senior level executives with strategic and operational responsibility for Sustainability, Corporate Responsibility, or ESG.



BSRT Participants and Collaborators

What we offer BSRT participants

Investor network

The BSRT has built an investor network from a range of asset owners and asset managers, represented by executives that are knowledgeable about the sector *and* about its sustainability issues.


Aberdeen	Chardan	Morgan Stanley	TPG Capital
Acadian	Credit Suisse	Novo Holdings	UBS
Achmea	Danske Bank	PGGM	Vancity
Allianz Global	Domini	Robeco	Vanguard
APG Asset Mgmt.	Federated Hermes EOS	Roche Pension	Wellington
Bank J. Safra Sarasin	Fidelity	Rockefeller Capital	
BlackRock	HSBC Asset Mgmt.	Schroders	
Calvert	Manulife	State Street	

Guests and collaborators

- Access Accelerated
- Access to Medicines Foundation
- Bill & Melinda Gates Foundation
- BIO
- Boston U. School of Public Health
- British Standards Institute
- BSR Healthcare Working Group
- Capitals Coalition
- CARB-X
- CDP
- CECP's CEO Investor Forum
- DuPont
- ECOFACT
- EFPIA
- EFRAG
- Future-Fit Foundation
- GBI
- GE Healthcare
- Gibson Dunn
- GRI
- Harvard Business School
- Health Outcomes Observatory, H₂O
- High Meadows Institute
- IFPMA
- Impact Management Project
- Impact-Weighted Accounts Project, Harvard Business School
- International Integrated Reporting Council
- ISSB/IFRS Foundation
- ISS ESG (oekom)
- MIT Sloan Sustainability Initiative
- MSCI
- NASDAQ CPH
- Oxford U. Saïd Business School
- Paxus LLP
- Polecat
- PSCI
- Purple Strategies
- Quantis
- RepRisk
- Rockefeller Foundation
- S&P Global
- SASB
- Shift
- SustainAbility (ERM)
- Sustainable Medicines Partnership
- Sustainalytics
- Swiss Re
- TNFD
- ThermoFisher
- UN Global Compact
- US Green Building Council
- Value Balancing Alliance
- Value Reporting Initiative
- WBCSD
- WifOR
- World Economic Forum
- Wharton Business School
- YewMaker

2023 BSRT Calendar of Activities

Evolving program developed with participating companies



	Q1	Q2	Q3	BSRT Conference	Q4
Topical Forums (online)		ESG Framework for Healthcare with IFPW, May 18 ESG Policy and Regulatory Outlook with EcoFact, Jun 13		Biopharma Sustainability Roundtable Annual Meeting 2023 Hosted by Organon , Jersey City – Oct 3-4 Biopharma Sustainability Investor Day 2023 Jay Conference Bryant Park, NYC – Oct 5	<i>Additional BSRT Forums in development</i>
Peer-to-Peer Networks and Annual Conference	BSRT Leaders Check-in Monthly – 2 nd Thursday Chief Sustainability Officer Council <i>New</i> Launch meeting, Feb 1	BSRT Leaders Check-in Monthly – 2 nd Thursday	BSRT Leaders Check-in Monthly – 2 nd Thursday		BSRT Leaders Check-in Monthly – 2 nd Thursday Chief Sustainability Officer Council Year-end session – Dec 5 Non-Executive Director Network <i>New</i> 2024 plans in development
Initiatives and their meetings	Biopharma Investor ESG Communications Initiative (Phase 5) Dialogs with Raters and Standard-setters: ISSB/SASB, Mar 29 Biopharma Human Rights Focus Group Expert Dialogs: Gibson, Dunn, Mar 2; Paxus, Mar 23	Biopharma Investor ESG Communications Initiative (Phase 5) Dialogs with Raters and Investors: MSCI, Apr 4; CDP, Apr 25; S&P Global, May 17; Achmea, Jun 23; PGGM, Jun 26; BlackRock, Jun 27; UBS, Jun 30 Biopharma Human Rights Focus Group Expert Dialogs: GBI, Apr 26; Shift, Jun 21 WG meeting: Jun21	Biopharma Investor ESG Communications Initiative (Phase 5) Dialogs with Standard-setters, Raters & Investors: Novo Holdings, Jul 3; ISS-ESG, Jul 21 Biopharma Human Rights Focus Group WG meeting — <i>date tbd</i>		Biopharma Investor ESG Communications Initiative 2024 plans in development Human Rights Focus Group 2024 plans in development
Insights			Biopharma Investor ESG Communications Initiative Guidance 4.0 Supplement (BSRT only) Biopharma Human Rights Focus Group Briefing: Human Rights in the Biopharma Sector (BSRT only)		

BSRT Agenda

Created every year in consultation with participants

Top-of-mind sustainability drivers

- Hot issues, challenges, risks, and opportunities for biopharma
- Company programs and activities

Sustainability governance

- Board oversight process
- Upskilling the Board and C-suite

Strategy and targets

- Long-term strategy and target setting
- Strategic relevance to business
- Sustainability-linked finance

Connecting sustainability with:

- Risk management
- Integrity and compliance
- Medical affairs
- Finance

Materiality

- Connecting materiality and strategy
- From analysis to action
- Single, double, and impact materiality

Sustainability reporting

- Regulations, Standards and frameworks: ISSB, SASB, IIRC, CSRD/ESRS, GRI, TNFD
- ESG data quality and management
- Reporting Tools and Software
- Integrated P&L
- Impact valuation (integrated financial, environmental and social reporting)

Access to medicine

- Access and healthcare infrastructure
- Drug Pricing
- Access and business model innovation
- Access Accelerated Initiative
- Access program building blocks
- Health outcomes and metrics

Environment

- Biodiversity - PiE and AMR
- Life-cycle perspective
- Green building trends and biopharma
- Green chemistry
- Sustainability, product development and stewardship

Engagement

- Community engagement
- Stakeholder engagement
- HR: goals and engagement

Supply chain

- Building strategic partnerships
- Sustainable procurement
- Risk assessment and monitoring
- Human rights risk in the supply chain

Biopharma response to:

- UN SDGs
- UN Guiding Principles
- UK Modern Slavery Act
- COP 21 (Paris Agreement)

Investor perspectives

- Material risks and opportunities
- Linking executive compensation and sustainability
- Connecting with Investor Relations
- Sustainability and valuation
- Value-based pricing
- Biopharma sustainability and mainstream investors
- How ESG performance information is really used
- ESG disclosure and investor engagement
- Evolution of ESG disclosure demands
- Sustainability-linked finance
- Future of external ESG evaluations

ESG ratings and rankings

- DJSI deep dive
- DJSI vs ATMI
- The ratings and rankings landscape
- Where's the value for biopharma

Emerging topics


- Sustainability policy and regulatory outlook, bi-annual update
- Scenario techniques
- Voice of the re-insurer on biopharma risks
- AI, big data, and cybersecurity

Potential topics for 2023 Forum and Conference

- **Access to Medicine** — How to measure impact?
- **Biodiversity** — Natural capital in biopharma, responding to biodiversity loss, company case studies and expert input (i.e., TNFD/Capitals Coalition)
- **Board and Executive Management** — ESG engagement and skills
- **Structuring and staffing biopharma sustainability and ESG operations** — Company case studies
- **Sustainability and ESG disclosure** — Navigating the evolving landscape (ISSB, CSRD/ESRS, SEC, etc.)
- **Linking ESG to compensation** — Sustainability-linked performance, from Board to all employees
- **Connecting ESG with clinical development** — Clinical trials, market strategy, and access to medicines
- **Digital and AI** — Connecting biopharma ESG and IT
- **Human Rights in the biopharma sector** — Update from the Biopharma Human Rights Focus Group
- **Product stewardship in biopharma** — Life-Cycle Analysis (LCA) and circularity for biopharma products
- **Thought leader conversations** — Corporate executives (CEOs, CFOs, NEDs), academics, and NGO visionaries

BSRT Value

Testimonials



“We quickly realized how valuable the Biopharma Sustainability Roundtable was. We found it highly relevant, with discussions that provided valuable information on topics we are working on right now. The open exchange with our peers helps us to better understand opportunities and challenges in pursuing our sustainability work.”

“The Biopharma Sustainability Conference was a fantastic meeting and rich discussion!”

“The Biopharma Sustainability Conference is particularly valuable because of its more intimate setting — not a large conference with many people in the room, but a smaller group that enables better interaction amongst the participants. I also think the BSRT team does a very good job selecting timely and relevant issues to explore.”

“The people behind BSRT are not only offering the best in-person and online events in our sector but are also incredibly valuable advisers based on sector expertise and insights which are second to none.”

“The Biopharma Investor ESG Communications Initiative and Guidance are drivers of influence and a resource base for standard-setters like SASB.”

“It was my pleasure to attend the Biopharma Sustainability Investor Day, an entirely different type of event which gave me lots of new perspectives on sustainable investment, both in general and the specific issues facing the pharma industry. Most certainly time well spent!”

“The Biopharma Sustainability Conference and Investor Day are an incredibly good use of my time – providing an excellent opportunity to learn from peers, share best practices, understand trends and get re-energized for the important work we all do. I emerge with practical learnings that I can apply immediately and which I am eager to share with colleagues.”

“The Biopharma Sustainability Investor Day was an interesting experience for me. The agenda was well composed, and the speakers gave a comprehensive insight into their topics. The event was moderated very professionally and there was enough time to discuss the topics in detail.”

“Thank you for the highly productive three days! It was like a boot-camp with a lot of learnings!”



Our History and Team

The Biopharma Sustainability Roundtable launched together with the initial SASB (now ISSB) standards for Biotechnology and Pharmaceuticals, in early 2013. For the first time, biopharma companies had a sector-focused, materiality-based sustainability forum. With encouragement from the original participants, Sandor Shoichet and Thomas Scheiwiller decided to repeat the program as an annual peer-to-peer discussion on sustainability-related trends, challenges, and best practices, that became known as “The Biopharma Sustainability Roundtable.” In 2015, the Biopharma Sustainability Roundtable expanded to include an ongoing Investor Dialog aimed at improving ESG communications with the capital market.

Myrto Kontaxi joined the team in 2016, taking the lead in developing the “Biopharma Investor ESG Communications Initiative” which launched in 2018, and has published a series of Biopharma Investor ESG Communications Guidance documents.

All our team members (Myrto, Sandor, and Thomas) also work as independent sustainability/ESG and strategy advisors both within and outside the biopharma sector.

Every year, we deliver a participant-driven program of online and in-person events, group initiatives, and bespoke advisory services.

Today, the Biopharma Sustainability Roundtable (BSRT for short) includes most large biotech and pharma companies globally as well as several medium- and smaller-scale biopharma businesses. BSRT is recognized as the leading biopharma sustainability forum within the sector and for connecting with its key stakeholders: Investors, Standard setters, Rating organizations, and Trade associations.

Sandor Schoichet

Partner and Co-Founder
San Francisco



Thomas Scheiwiller

Partner and Co-Founder
Zurich



Myrto Kontaxi

Partner
Boston



Contact us

info@biopharmasustainability.com
BiopharmaSustainability.com

Follow us 